This program is designed to raise awareness and close knowledge gaps for medical oncologists, surgeons, dermatologists, oncology nurses, and oncology pharmacists regarding the expanding use of ICIs to treat patients with melanoma. It addresses investigational neoadjuvant and adjuvant therapy with ICIs, especially in the earlier stages of the disease. It includes the scientific rationale driving research, clinical trial surrogate endpoints, predictive biomarkers, mechanisms of disease resistance under investigation, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges. The program allows busy clinicians to hear from the experts on critical takeaways from research studies and implications for current practice, such as treatment selection and effective management of treatment-related AEs.